Christopher Arthur

3.3k total citations · 2 hit papers
46 papers, 2.0k citations indexed

About

Christopher Arthur is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Christopher Arthur has authored 46 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 22 papers in Genetics and 9 papers in Oncology. Recurrent topics in Christopher Arthur's work include Chronic Myeloid Leukemia Treatments (23 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Acute Myeloid Leukemia Research (10 papers). Christopher Arthur is often cited by papers focused on Chronic Myeloid Leukemia Treatments (23 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Acute Myeloid Leukemia Research (10 papers). Christopher Arthur collaborates with scholars based in Australia, United States and France. Christopher Arthur's co-authors include Susan Branford, Andrew Grigg, Timothy P. Hughes, Anthony P. Schwarer, John F. Seymour, Robin Filshie, Anthony K. Mills, David M. Ross, Xavier Thomas and Hagop M. Kantarjian and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Christopher Arthur

44 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2012 818 citations Hagop M. Kantarjian, Xavier Thomas et al. Journal of Clinical Oncology profile →
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

2013 508 citations David M. Ross, Susan Branford et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Christopher Arthur	1.7k	954	551	477	348	46	2.0k
Gareth Gerrard	1.3k 0.8×	984 1.0×	505 0.9×	478 1.0×	399 1.1×	75	2.2k
G. Alimena	1.3k 0.7×	832 0.9×	331 0.6×	409 0.9×	305 0.9×	31	1.6k
Valentín García‐Gutiérrez	1.7k 1.0×	1.4k 1.5×	256 0.5×	768 1.6×	390 1.1×	104	2.0k
Jamshid S. Khorashad	2.4k 1.4×	2.1k 2.2×	283 0.5×	1.2k 2.5×	304 0.9×	67	2.9k
Beatriz Moiraghi	1.8k 1.1×	1.5k 1.6×	222 0.4×	1.0k 2.1×	309 0.9×	42	2.1k
Rolf Billström	1.2k 0.7×	473 0.5×	538 1.0×	156 0.3×	185 0.5×	58	1.7k
Ester Orlandi	1.2k 0.7×	1.3k 1.3×	360 0.7×	476 1.0×	546 1.6×	95	2.4k
Philippe Mineur	625 0.4×	638 0.7×	400 0.7×	165 0.3×	257 0.7×	49	1.4k
Saengsuree Jootar	1.2k 0.7×	915 1.0×	144 0.3×	514 1.1×	199 0.6×	75	1.5k
Helmut Löffler	2.1k 1.2×	591 0.6×	882 1.6×	147 0.3×	247 0.7×	47	2.5k

Countries citing papers authored by Christopher Arthur

Since Specialization

Citations

This map shows the geographic impact of Christopher Arthur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Arthur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Arthur more than expected).

Fields of papers citing papers by Christopher Arthur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Arthur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Arthur. The network helps show where Christopher Arthur may publish in the future.

Co-authorship network of co-authors of Christopher Arthur

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Arthur. A scholar is included among the top collaborators of Christopher Arthur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Arthur. Christopher Arthur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deininger, Michael W., Jane Apperley, Christopher Arthur, et al.. (2024). Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.. Journal of Clinical Oncology. 42(16_suppl). 6501–6501.

Gardiner, F, Alice Richardson, C Roxburgh, et al.. (2021). Characteristics and in‐hospital outcomes of patients requiring aeromedical retrieval for pregnancy, compared to non‐retrieved metropolitan cohorts. Australian and New Zealand Journal of Obstetrics and Gynaecology. 61(4). 519–527. 5 indexed citations

Shen, Yandong, Luke Coyle, Ian Kerridge, et al.. (2021). Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. SHILAP Revista de lepidopterología. 3(1). 129–138. 14 indexed citations

Gritti, Giuseppe, Paula Marlton, Tycel Phillips, et al.. (2020). Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. Blood. 136(Supplement 1). 45–47. 16 indexed citations

Othman, Jad, Christopher Arthur, Keith Fay, et al.. (2020). Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma. Bone Marrow Transplantation. 55(7). 1460–1463. 3 indexed citations

Lindsay, Julian, Albert Kai-Sun Wong, Ian Kerridge, et al.. (2019). Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens. Bone Marrow Transplantation. 55(8). 1638–1641. 1 indexed citations

Ross, David M., Ilaria S. Pagani, Naranie Shanmuganathan, et al.. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 32(12). 2572–2579. 56 indexed citations

Barron, Melissa L., Mark S. Rybchyn, Rebecca S. Mason, et al.. (2017). Clinical, cellular, microscopic, and ultrastructural studies of a case of fibrogenesis imperfecta ossium. Bone Research. 5(1). 16057–16057. 5 indexed citations

Arthur, Christopher, Jaroslav Čermák, Jacques Delaunay, et al.. (2015). Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Journal of Blood Medicine. 6. 25–25. 3 indexed citations

10.

Lickliter, Jason D., Kerry Taylor, Jeff Szer, et al.. (2014). An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. Leukemia & lymphoma. 56(3). 630–638.

11.

Thomas, Xavier, et al.. (2013). A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 14(1). 68–72. 17 indexed citations

12.

Kantarjian, Hagop M., Xavier Thomas, Anna Dmoszyńska, et al.. (2012). Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology. 30(21). 2670–2677. 818 indexed citations breakdown →

13.

Ross, David M., Susan Branford, John F. Seymour, et al.. (2010). Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 24(10). 1719–1724. 194 indexed citations

14.

Arthur, Christopher, et al.. (2008). Assessing the impacts of tropical cyclones. Australian Journal of Emergency Management. 23(4). 14–20. 9 indexed citations

15.

Arthur, Christopher, et al.. (2005). Inflatable rescue boat-related injuries in Queensland surf lifesavers: the epidemiology – biomechanics interface. International Journal of Injury Control and Safety Promotion. 12(1). 39–44. 4 indexed citations

16.

Bentley, Michael A., Paula Marlton, N. Horvath, et al.. (2003). Single dose per cycle pegfilgrastim successfully supports full dose intensity CHOP-14 in patients over 60 years with non-Hodgkin's lymphoma (NHL) and successfully mobilises peripheral blood progenitor cells (PBPC).. Blood. 102(11). 5 indexed citations

17.

Nivison‐Smith, Ian, KF Bradstock, Jeff Szer, et al.. (2001). Allogeneic haemopoietic cell transplants in Australia, 1996 – A multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. Bone Marrow Transplantation. 28(1). 21–27. 13 indexed citations

18.

Arthur, Christopher, et al.. (1993). Combined Interferon Alfa-2a and Cytosine Arabinoside as First-Line Treatment for Chronic Myeloid Leukemia. Acta Haematologica. 89(1). 15–21. 40 indexed citations

19.

Arthur, Christopher, et al.. (1991). Effects of taipan (Oxyuranus scutellatus) venom on erythrocyte morphology and blood viscosity in a human victim in vivo and in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene. 85(3). 401–403. 12 indexed citations

20.

Hibbin, Jill, et al.. (1988). Use of minisatellite DNA probes for recognition and characterization of relapse after allogeneic bone marrow transplantation. British Journal of Haematology. 68(2). 195–201. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact